Company*
(Country; Symbol)
Company*
(Country;  Symbol)
Type/Product Area Terms/Details (Date)

JUNE
 
Collegium Pharmaceutical Inc.* Lupin Ltd. (India; Bombay: LUPIN) Agreement for Collegium to sell Lupin all worldwide rights to AllerNaze nasal spray for nasal symptoms associated with both seasonal allergic rhinitis and perennial allergic rhinitis in adults and children Financial terms were not disclosed (6/30)
 
EpiCept Corp. (EPCT) IDIS* (UK) Agreement to administer a named patient program for Ceplene, which is approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia Ceplene is now available in advance of its commercial launch later this year (6/2)
 
Immuno-Cellular Therapeutics Ltd. (OTC BB:IMUC) Formatech Inc.* Agreement for the manufacture of IMUC's cancer stem cell vaccine candidate, ICT-121, for an upcoming Phase I trial The study will target glioblastoma; financial terms were not disclosed (6/24)
 
MediGene AG (Germany; FSE:MDG) Juste SAQF* (Spain) Marketing partnership for the commercialization of Veregen ointment in Spain and Portugal Juste will promote and distribute the drug for the treatment of genital warts; MediGene could receive $3.58M in payments plus royalties (6/23)
 
Nuvo Research Inc. (Canada; TSX: NRI) Covidien Inc. (NYSE:COV) Agreement to commercialize Pennsaid for osteoarthritic knee pain Covidien is paying Nuvo $10M up front and $15M more if the lotion wins FDA clearance, an amount that could increase to $20M if the agency agrees to certain labeling criteria (6/16)
 
Penwest Pharmaceuticals Co. (PPCO) and Endo Pharmaceuticals Holdings Inc. (ENDP) Valeant Pharmaceuticals International (NYSE:VRX) Exclusive license allowing Valeant to market Opana ER in Canada, Australia and New Zealand Valeant agreed to pay C$2M (US$1.8M) up front, plus payments totaling up to C$1M when certain sales milestones are reached in Canada and up to A$1.1M (US$881,402) when certain regulatory and sales milestones are met in Australia (6/9)
 
Vivalis (France; Paris:VLS) Unnamed company Agreement to produce monoclonal antibodies on  its EB66 cell line platform, derived from duck embryonic stem cells Vivalis has signed seven new commercial licenses since January (6/30)
 
JULY
 
Horizon Discovery Ltd.* SuperGen Inc. (SUPG) Commercial agreement relating to its X-MAN technology It covers the screening of lead compounds on a wide panel of human isogenic cell lines comprising target genotypes of interest to SuperGen (7/15)
 
Kineta Inc.* Airmid Inc.* Agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid The array of compounds holds potential for the treatment of multiple sclerosis (7/7)
 
Medarex Inc. (MEDX) Lonza Group Ltd. (Switzerland; LSE: LNA) Manufacturing agreement for Medarex's pipeline of therapeutic proteins and antibody-drug conjugates Financial terms were not disclosed (7/9)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.